Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma.
Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma.
复制标题
噻替派、白消安和环磷酰胺：高危多发性骨髓瘤自体骨髓或造血干细胞移植的新准备方案。
作者：
M. Dimopoulos;R. Alexanian;D. Przepiorka;J. Hester;B. Andersson;S. Giralt;R. Mehra;K. V. Besien;K. Delasalle;C. Reading
40例多发性骨髓瘤患者接受噻替派（750 mg/m2）、白消安（10 mg/kg）和环磷酰胺（120 mg/kg）（TBC），随后接受自体骨髓或造血干细胞支持。给予粒细胞集落刺激因子（G-CSF）以加速造血恢复。65%的患者对这种治疗有反应。88%的移植患者部分缓解，骨髓瘤进一步减少，53%达到完全缓解。48%的难治性骨髓瘤患者有反应。在部分缓解期间移植的所有反应患者或患有原发性难治性骨髓瘤的患者在移植后4至24个月内保持无进展，但在难治性复发中治疗的患者的缓解持续时间较短（4个月）。24例接受骨髓移植的患者中有5例死于治疗相关并发症，16例接受造血干细胞移植的患者中无一例死于治疗相关并发症。使用造血干细胞导致粒细胞和血小板恢复更快。我们的结论是，TBC是一种有效的，相对耐受性好，多发性骨髓瘤患者的准备方案。
Forty patients with multiple myeloma received thiotepa (750 mg/m2), busulfan (10 mg/kg), and cyclophosphamide (120 mg/kg) (TBC) followed by autologous bone marrow or blood stem cell support. Granulocyte-Colony stimulating factor (G-CSF) was administered to accelerate hematopoietic recovery. Sixty-five percent of all patients responded to this treatment. Eighty-eight percent of patients transplanted in partial remission had a further reduction of the myeloma and 53% achieved a complete remission. Forty-eight percent of patients with refractory myeloma responded. All responding patients transplanted during partial remission or with primary refractory myeloma remain free of progression for a period of 4 to 24 months post-transplant, but the remission duration of patients treated in refractory relapse was short (4 months). Five of 24 patients transplanted with marrow and none of 16 receiving blood stem cells died of treatment-related complications. Use of blood stem cells resulted in more rapid granulocyte and platelet recovery. We conclude that TBC is an effective, relatively well tolerated, preparative regimen for patients with multiple myeloma.
登录
查看更多内容
影响因子：
158.5
作者：
BARLOGIE, B;SMITH, L;ALEXANIAN, R
通讯作者：
ALEXANIAN, R
影响因子：
158.5
作者：
SANTOS, GW;TUTSCHKA, PJ;YEAGER, AM
通讯作者：
YEAGER, AM
影响因子：
45.3
作者：
BEARMAN, SI;APPELBAUM, FR;THOMAS, ED
通讯作者：
THOMAS, ED
白消安和环磷酰胺为多发性骨髓瘤患者进行同种异体骨髓移植做准备的 I 期研究。
DOI：
10.1200/jco.1992.10.9.1492
发表时间：
1992
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Bensinger,WI;Buckner,CD;Clift,RA;Petersen,FB;Bianco,JA;Singer,JW;Appelbaum,FR;Dalton,W;Beatty,P;Fefer,A
通讯作者：
Fefer,A
采用自体骨髓和造血干细胞支持联合治疗多发性骨髓瘤的低风险强化治疗。
影响因子：
20.3
作者：
Jagannath,S;Vesole,DH;Glenn,L;Crowley,J;Barlogie,B
通讯作者：
Barlogie,B